EMERYVILLE, CALIF. — Sep. 18, 2008
Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) today announced that it will present at the UBS Global Life Sciences Conference on Wednesday, September 24, at 4:30 p.m. Eastern Time. Interested parties may access a live webcast of the presentation on our website at:
It is recommended that listeners log on 15 minutes early in order to register and download any necessary software. For those unable to participate during the live webcast, a recorded replay of the presentation will be available within 24 hours of the completion of the presentation through October 24, 2008.
Onyx Pharmaceuticals, Inc. is a biopharmaceutical company committed to improving the lives of people with cancer by changing the way cancer is treatedTM. The company, in collaboration with Bayer HealthCare Pharmaceuticals, Inc., is developing and marketing Nexavar®, a small molecule drug. Nexavar is currently approved for the treatment of liver cancer and advanced kidney cancer. Additionally, Nexavar is being investigated in several ongoing trials in non-small cell lung cancer, melanoma, breast cancer, and other cancers. For more information about Onyx, visit the company’s website at www.onyx-pharm.com.
Nexavar® (sorafenib) tablets is a registered trademark of Bayer Pharmaceuticals Corporation.Return to 2008 Press Releases